Ultragenyx Pharmaceutical (RARE) Earning Somewhat Positive Press Coverage, Accern Reports

Media stories about Ultragenyx Pharmaceutical (NASDAQ:RARE) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ultragenyx Pharmaceutical earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.0666179812321 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Ultragenyx Pharmaceutical (RARE) opened at $47.63 on Thursday. The firm has a market capitalization of $2,080.28, a price-to-earnings ratio of -6.83 and a beta of 1.89. Ultragenyx Pharmaceutical has a twelve month low of $41.67 and a twelve month high of $91.35.

Several brokerages have recently issued reports on RARE. BidaskClub lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, February 9th. Canaccord Genuity set a $80.00 price target on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Thursday, November 16th. Robert W. Baird cut their price objective on Ultragenyx Pharmaceutical from $85.00 to $80.00 and set an “outperform” rating on the stock in a report on Friday, November 3rd. Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. Finally, Credit Suisse Group initiated coverage on Ultragenyx Pharmaceutical in a report on Wednesday, January 17th. They set an “outperform” rating and a $67.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $72.06.

TRADEMARK VIOLATION NOTICE: “Ultragenyx Pharmaceutical (RARE) Earning Somewhat Positive Press Coverage, Accern Reports” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/15/ultragenyx-pharmaceutical-rare-earning-somewhat-positive-press-coverage-accern-reports.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply